Deep Expertise Across Functional Areas
Bringing together industry experts, blue-chip investors, and a cross-disciplinary team of top scientists in antibody drug discovery and disease biology, we are translating therapeutics into the clinic. Meet our Leadership Team:
Dr. Vickers is the Chief Executive Officer of Northern Biologics, and a member of the Northern Biologics Board of Directors. Prior to joining Northern Biologics, Dr. Vickers served as Global Head of Research and Development and a member of the Executive Committee of Shire, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. Under Dr. Vickers’s leadership Shire’s pipeline had approximately 40 programs in clinical development in the areas of Genetic Disease, GI disease, Hematology, Immunology, Neuroscience, Ophthalmology and Oncology. Prior to Shire, Dr. Vickers held positions of increasing responsibility in Research and Development at Merck, Pfizer, Boehringer-Ingelheim and Resolvyx Pharmaceuticals. Dr. Vickers is also a member of the Board of Directors of Revance Therapeutics and AVROBIO.
Dr. Vickers obtained his PhD in Biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
Lina Gugucheva joined Northern Biologics as Chief Business Offer in November 2019. Prior to joining Northern, Ms. Gugucheva served as Vice President, Business Development & Strategy at IFM Therapeutics. At IFM, Ms. Gugucheva led the structuring, negotiation and execution of multiple debt and equity financings in excess of $100M across multiple IFM subsidiaries. Ms. Gugucheva also spearheaded IFM’s business development efforts, leading IFM’s negotiations for the successful $1.58B sale of IFM Tre, IFM’s NLRP3 antagonist-focused subsidiary, to Novartis in May 2019, as well as the $880M collaboration and exclusive option agreement between Novartis and IFM Due, IFM’s subsidiary, to develop novel immunotherapies inhibiting the cGAS/STING pathway in August 2019.
Ms. Gugucheva began her career as a life sciences transactional associate at the law firm of Covington & Burling. Ms. Gugucheva was then Vice President, Investments & Counsel at Royalty Pharma where she negotiated a series of transactions including the $2.85 billion purchase of a royalty interest on sales of the multiple sclerosis drug, TYSABRI®. Ms. Gugucheva holds a J.D. from Harvard Law School and a B.A. in molecular biology and political science from New York University.
Dr. Sweeney is the Chief Business Officer of Northern Biologics. Dr. Sweeney started his professional career as an investment professional at VenGrowth Private Equity Partners. He then joined Tornado Medical Systems, a revenue stage, high performance medical instruments company, as one of its founding members. Dr. Sweeney was then recruited to lead Business Development and Strategy at T2 Biosystems. During his tenure at T2Bio, the company grew from a venture-backed start-up to a revenue stage, FDA approved, NASDAQ publicly listed company.
Prior to joining Northern Biologics, Dr. Sweeney was Vice-President of Corporate Development & Head of Strategic Financing at bioMerieux - a world leader in the field of in vitro diagnostics with annual revenues of € 2.3 billion, employing over 10,000 people worldwide. Dr. Sweeney had global responsibilities for technology scouting and strategic partnerships. Moreover, he was responsible for all aspects of bioMerieux’s strategic investments in early stage companies.
Dr. Sweeney is a graduate of the Molecular and Medical Genetics Department of the University of Toronto, and obtained his PhD as a Terry Fox Scholar studying the molecular mechanisms of cell cycle checkpoints and DNA repair. He currently holds an Adjunct Professor position at the University of Toronto where he teaches a graduate level course on Entrepreneurship in Life Sciences.
Dr. Wasserman is the Chief Medical Officer at Northern Biologics as of December, 2016. Dr. Wasserman’s expertise lies in oncology translational medicine, including preclinical, clinical, biomarker and companion diagnostic drug development. From May 2014 through November 2016, Dr. Wasserman was responsible for leading the medical strategy for Oncology and Malignant Hematology as the Global Therapeutic Area Head for Covance, the CRO division of LabCorp. Dr. Wasserman was the leader for the physician group that monitors global and regional Oncology trials for clients, and he led the cross-business unit team responsible for educating employees and promoting their Immuno-Oncology expertise and capabilities as part of a corporate strategic initiative.
Before joining Covance, Dr. Wasserman spent 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as Site Head of Academic Alliances, Pharma Research and Early Development (pRED) for the Translational Clinical Research Center. Prior to his employment at Roche, he was the Deputy Director of the Oncology Biomarker group at Novartis after starting his pharmaceutical career at Merck. Dr. Wasserman earned his M.D. from Johns Hopkins University School of Medicine, and completed his Pediatric Residency and Pediatric Hematology-Oncology fellowship training at The Children’s Hospital of Philadelphia, University of Pennsylvania. After completing his training, he stayed on as an Assistant Professor for nine years.
Darlene Deptula-Hicks joined Northern Biologics in March 2018 as consulting Chief Financial Officer. Ms. Deptula-Hicks, is an accomplished financial executive in the life sciences and medical technology industries and has nearly 30 years’ experience leading financial operations for both public and private companies. She brings to Northern Biologics a proven track record in finance strategy leadership, capital raising, mergers and acquisitions, operational management and the ability to build strong, external partnerships. Prior to Northern Biologics, Ms. Dupta-Hicks served as Sr. Vice President and Chief Financial Officer and Treasurer of T2 Biosystems, Inc. (NASDAQ:TTOO) and Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) where she was responsible for financial strategy, capital formation, compliance and reporting and investor relations. Prior to T2 and Pieris, Ms.Deptula-Hicks served as the CFO for a variety of biotechnology and medical device companies, including in the areas of oncology, genomics, minimally invasive surgery, advanced image analysis, radiation oncology, cardiology and orthopedics, among other specialties.
Ms. Deptula-Hicks completed an executive education program at Dartmouth College’s Tuck School of Business and received her MBA from Rivier College. She received her bachelor’s in accounting from Southern New Hampshire University, and has served on a variety of public and private company boards.
Dr. Anido joined Northern Biologics as VP of Operations and Corporate Affairs in June 2017. Previously, Dr. Anido was co-founder of Mosaic Biomedicals, a Barcelona-based company that develops personalized cancer treatments with a dual mechanism of action targeting cancer stem cells and the tumor’s immune system. As Mosaic’s CEO, Dr. Anido led the growth of the company until its merger with Northern in 2016. Prior to Mosaic, Dr. Anido was Associate at the Pipeline and Portfolio Planning team collaborating with the Oncology & Hemathology Franchise at Genentech Inc. (CA, US).
Dr. Anido holds a Master in Business Administration (MBA) from Duke University (NC, US) with a certification in Health Sector Management and concentration in Entrepreneurship and Innovation. In addition, she received her PhD from the University of Barcelona (Spain) and has over 10 years of scientific career in translational oncology at the Vall d’Hebron Institute of Oncology (Spain). Dr. Anido is a recipient of merit-based scholarships from the Spanish Association Against Cancer (AECC), Rafael del Pino Foundation, Caja Madrid Foundation and Duke University’s Julian Connally Scholarship.
Dr. Hulme is Vice-President and Head of Research at Northern Biologics. Dr. Hulme joined Northern Biologics in 2015 as Director of Fibrosis, where she led the fibrosis team and developed and advanced several innovative antibody therapeutics for the treatment of fibrotic diseases. In 2018 Dr. Hulme assumed the leadership of Northern's immuno-oncology portfolio and in 2019 was promoted to Vice-President and Head of Research. Prior to joining Northern Biologics, Dr. Hulme held positions of increasing responsibility in Inflammation Research at Amgen. During her eight years at Amgen, Dr. Hulme led cross-functional preclinical teams developing innovative small molecule and protein therapeutics for inflammatory diseases, fibrosis and immuno-oncology.
Dr. Hulme obtained her PhD in Pharmacology from the University of Leeds, UK, which was followed by postdoctoral research in mechanisms of ion channel regulation at the University of Washington, Seattle.
Ms. LeClair joined Northern Biologics in January 2018 as Head of Human Resources. As a Senior HR Consultant, Ms. LeClair has broad expertise in human resources, finance and communications. With over 20 years’ experience working with biotech start-ups; researchers, clinicians, CEO’s and boards of directors she has worked both in the private and public sector.
Ms. LeClair previously served on the board with BioTalent Canada for two consecutive 3-year terms and a year with the York Technology Association (now TechConnex). Currently, she is a member of the board of directors for JobStart, a not-for-profit organization with a mandate to help job seekers attain economic self sufficiency. She currently serves as Chair of the Nominating Committee and Board Secretary.
She is a graduate of the Rotman School of Management’s Advanced Program in Human Resources, University of Toronto. As a member of the Human Resource Professionals Association (HRPA), she holds a Certified Human Resource Leader (CHRL) designation.